The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
The results of our study demonstrate the efficacy and safety of nivolumab plus chemotherapy in real-world practice support its adoption as a new standard first-line treatment for patients with advanced HER2-negative GC, particularly those with CPS ≥ 5.
Authors
- Yuyin Liu (ORCID: https://orcid.org/0000-0002-4995-832X)
- Yen‐Hao Chen (ORCID: https://orcid.org/0000-0002-5622-5490)
- Tingting Liu (ORCID: https://orcid.org/0000-0002-1725-7748)
- Yu‐Hung Lin (ORCID: https://orcid.org/0000-0001-5116-8899)
- Cheng-Hsi Yeh (ORCID: https://orcid.org/0000-0002-0632-487X)
- Yu-Cheng Lin
- Ming-Yen Tsai
- Yueh-Wei Liu
Institutions
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s12885-024-13066-z
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Chang Gung Medical Foundation
- Kaohsiung Chang Gung Memorial Hospital